NGS Genomic Test · Circulating Cell-Free Fetal DNA (cfDNA)

POCAdvance
cfDNA Genetics

Order the test

POCAdvance cfDNA Genetics

POCAdvance cfDNA Genetics is a non-invasive genetic test that, through analysis of circulating cell-free fetal DNA (cfDNA) from a maternal blood sample, investigates genetic determinants associated with recurrent spontaneous miscarriage not attributable to a chromosomal abnormality.

The test uses high-sensitivity, high-resolution massively parallel sequencing technologies (Next Generation Sequencing – NGS), enabling targeted molecular evaluation of genetic factors predisposing to recurrent pregnancy loss.

Test specifications

Non-invasive (maternal blood sample)
Targeted evaluation of genetic causes predisposing to recurrent pregnancy loss
Sequencing of the coding regions of approximately 7,000 genes
Turnaround time: ~15 working days
CIRCULATING CELL-FREE FETAL DNA (cfDNA)

During pregnancy, the placenta physiologically releases DNA fragments into the maternal circulation (apoptosis), starting from approximately the 5th week of gestation. This material is defined as circulating cell-free fetal DNA (cfDNA). Close to a miscarriage event, placental tissue may continue to release cfDNA into the maternal blood, making it possible to perform non-invasive investigations immediately after the ultrasound diagnosis of spontaneous pregnancy loss, with the aim of obtaining information useful on the potential genetic contribution.

Advantages of cfDNA analysis over traditional methods

POCAdvance cfDNA Genetics overcomes the main limitations of classical cytogenetic karyotyping, offering significant technical and clinical advantages.

Non-invasiveness

Performed with a simple maternal blood draw, without requiring surgical procedures or cell culture of the miscarriage tissue.

Timeliness

Applicable from the early stages of gestation (≥ 5 weeks)

Clinically useful timing

Can be performed before any uterine evacuation procedure

Two levels of analysis

The diagnostic workflow offers two possible levels of analysis: targeted analysis of a panel of genes specifically associated with the condition, or a broader Clinical Exome Sequencing investigation.

FOCUS

Targeted analysis of 19 genes in which pathogenic variants have been associated with non-chromosomal recurrent spontaneous pregnancy loss.

Genes Analyzed
NLRP7 (NALP7)
KHDC3L
SYCP3
HLA-G
WNT6
CEP250
CGB
NLRP10
PROKR1
FOXP3
OSBPL5
C4BPA
ANXA5
CD46
REC114
FOXD1
NLRP5
PADI6
TLE6

EXOME

Clinical Exome Sequencing: sequencing of the coding regions of approximately 7,000 genes, including genes known to be associated with pregnancy loss and related phenotypes.

Clinical relevance

Identification of a pathogenic variant in one of the analyzed genes suggests a possible genetic determinant associated with recurrent spontaneous pregnancy loss and may support more informed reproductive planning and personalized counseling.

Technology: high resolution and advanced bioinformatics

Blood
sample
collection
cfDNA
isolation
NGS
sequencing
Bioinformatic analysis
with proprietary
algorithm
REPORT
Report
delivery

FOCUS

Full exon sequencing (whole-exon sequencing) of the panel genes

EXOME

Clinical Exome Sequencing (~7,000 genes)

ADVANCED PIPELINE

Advanced pipeline for variant detection, annotation, and prioritization.

Interpretation of results

Positive

Pathogenic variant detected

Clinical significance should be interpreted in the context of: reproductive and clinical history, laboratory/instrumental findings, cytogenetic/cytogenomic results.

Negative

No pathogenic variant detected

This does not exclude a genetic basis, as the cause may involve: genes not included in the panel (FOCUS level), variants in regions not investigated or not fully assessable, non-genetic multifactorial determinants

Test indications

POCAdvance cfDNA Genetics is particularly indicated in the following clinical settings:

  • spontaneous miscarriage (anembryonic gestational sac, absence of cardiac activity, miscarriage in progress) when a timely, non-invasive investigation is desired;
  • history of recurrent pregnancy loss with no identified chromosomal cause;
  • repeated pregnancy losses in the absence of an exhaustive clinical explanation.

How to order the test

Kit
request
Documentation
completion
Sample
collection
Sample
shipment
Report
delivery

Blood draw timing

The blood sample should be collected as soon as possible after ultrasound confirmation of pregnancy loss and before any uterine evacuation procedure; alternatively, within 24 hours of expulsion of the products of conception.

The test can be performed in singleton or twin pregnancies (monozygotic or dizygotic) at ≥ 5 weeks of gestation.

Turnaround time: ~15 working days

Brochure

Request information about POCAdvance cfDNA GENETICS

Fill in the form for a free consultation. One of our geneticists will contact you, with no obligation, to provide all the information you need.

Free consultation with a specialized geneticist
Response within 24 working hours
Data processed in compliance with the GDPR